Skip to main content
Clinical Trials/NCT04637035
NCT04637035
Active, Not Recruiting
N/A

Feasibility of Delivering a Supportive Oncology Care at Home Intervention for Hospitalized Patients With Cancer

Massachusetts General Hospital2 sites in 1 country110 target enrollmentAugust 19, 2021

Overview

Phase
N/A
Intervention
Supportive Oncology Care at Home
Conditions
Cancer
Sponsor
Massachusetts General Hospital
Enrollment
110
Locations
2
Primary Endpoint
Rates of study enrollment
Status
Active, Not Recruiting
Last Updated
11 days ago

Overview

Brief Summary

This study is evaluating if a program that involves remote monitoring and home-based care may improve the post-discharge care of recently hospitalized patients with advanced cancer.

The Supportive Oncology Care at Home intervention consists of three key components:

  1. Remote patient monitoring (e.g. patient-reported symptoms, home-monitored vital signs and body weight);
  2. A Medically Home care model for symptom assessment, evaluation, and management (e.g. triggers for phone calls and visits to patients' homes to address and manage any concerning issues identified);
  3. Structured communication with the oncology team to ensure continuity of care.

Detailed Description

This is a single-arm pilot study of recently hospitalized patients with advanced cancer to assess the the feasibility of delivering a remote monitoring and home-based program, Supportive Oncology Care at Home, the acceptability and satisfaction with the Supportive Oncology Care at Home program, and changes in the quality of life and symptoms of patients who receive the Supportive Oncology Care at Home program. Oncologists at the MGH Cancer Center developed the Supportive Oncology Care program to address the symptoms and frequent hospital visits that patients face as a result of their cancer and the treatment they receive. The research study procedures include: * Remote monitoring of symptoms, vital signs, and body weight * Questionnaires asking about demographic information (e.g. gender, ethnicity, income) and participant experience with cancer (e.g. your quality of life, your symptoms) * Interviews to assess participant impressions of the program * Caregiver Interviews, Questionnaires and Surveys to assess caregiver impressions of the program and caregiver perceptions of participant symptoms while in the program * Clinician Interviews and Questionnaires to assess impressions of the program * Data collection from participant medical record. Patients will take part in the program for two weeks following hospital discharge. It is expected that between 75 and 110 people will enroll, including up to 30 patients, up to 30 caregivers, and up to 15 clinicians. Medically Home Group, Inc. is supporting this research study by providing funding for this research study.

Registry
clinicaltrials.gov
Start Date
August 19, 2021
End Date
December 31, 2026
Last Updated
11 days ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Ryan Nipp

Principal Investigator

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Patient Eligibility
  • Age 18 or older
  • Diagnosed with advanced cancer (defined as receiving treatment with palliative intent per chemotherapy order entry treatment intent designation and/or trial consent forms OR based on documentation in the oncology clinic notes for those not receiving chemotherapy)
  • Admitted with an unplanned or non-elective hospitalization at Massachusetts General Hospital (MGH)
  • Not requiring ICU-level care during their hospitalization
  • Receiving care at the MGH Cancer Center
  • Ability to read and respond to question in English
  • Residing within 50 miles of MGH.
  • Caregiver Eligibility
  • Relative or friend of eligible patient

Exclusion Criteria

  • Patient Exclusion
  • Are admitted to the intensive care unit
  • Have a high oxygen requirement (FIO2 \> 0.40)
  • Experience active angina or cardiac arrythmias
  • Have a planned inpatient surgical or interventional procedure
  • Have uncontrolled psychiatric illness or impaired cognition interfering with their ability to understand study procedures and provide written informed consent
  • Are deemed ineligible for home-based care based on the inpatient oncology clinician assessment
  • Are planning to be discharged to hospice or to any location other than their home
  • Caregiver Exclusion -- Caregivers who are unwilling or unable to participate in the study.
  • Clinician Exclusion

Arms & Interventions

Supportive Oncology Care at Home

Participants will receive the Supportive Oncology Care at Home program for 14 days following their discharge from the hospital. The Supportive Oncology Care at Home intervention consists of three key components: * Daily monitoring of patient-reported symptoms, vital signs, and body weight. * Medically Home care based on algorithmic changes in patients' daily symptoms, vital signs, and body weight. * Structured communication with the oncology team regarding care delivered to ensure continuity of care.

Intervention: Supportive Oncology Care at Home

Outcomes

Primary Outcomes

Rates of study enrollment

Time Frame: 2 years

Proportion of patients who agree to participate in the study and sign informed consent.

Rates of completion of daily symptom assessment

Time Frame: 2 years

Proportion of daily patient-reported symptom assessments completed throughout the study period.

Secondary Outcomes

  • Rates of completion of daily vital signs(2 years)
  • Rates of completion of daily body weight(2 years)
  • Number of home visits required(Baseline to 2 weeks post-enrollment)
  • Duration of home visits(Baseline to 2 weeks post-enrollment)
  • Issues addressed during home visits(Baseline to 2 weeks post-enrollment)
  • Interventions delivered during home visits(Baseline to 2 weeks post-enrollment)
  • Number of phone calls required(Baseline to 2 weeks post-enrollment)
  • Duration of phone calls(Baseline to 2 weeks post-enrollment)
  • Number of emails required(Baseline to 2 weeks post-enrollment)
  • Patient acceptability(1 year)
  • Family caregiver acceptability(1 year)
  • Clinician acceptability(1 year)
  • Change in symptoms burden longitudinally throughout the study(Baseline to 2 weeks post-enrollment)
  • Change in psychological distress score longitudinally throughout the study(Baseline to 2 weeks post-enrollment)
  • Change in quality of life score longitudinally throughout the study(Baseline to 2 weeks post-enrollment)
  • Change in care satisfaction score longitudinally throughout the study(Baseline to 2 weeks post-enrollment)
  • Number of emergency department visits(Baseline up to one month post-enrollment)
  • Rates of emergency department visits(1 year)
  • Number of urgent visits(Baseline up to one month post-enrollment)
  • Rates of urgent visits(1 year)
  • Number of hospital readmissions(Baseline up to one month post-enrollment)
  • Rates of hospital readmissions(1 year)
  • Length of hospital readmissions(Baseline up to one month post-enrollment)
  • Days outside of hospital(Baseline to 2 weeks post-enrollment)
  • Hospitalization length of stay(Baseline to 2 weeks post-enrollment)
  • Change in caregivers reports of patients' symptom burden longitudinally throughout the study(Baseline to 2 weeks post-enrollment)
  • Concordance between caregiver and patient reports of patient symptom burden(Baseline to 2 weeks post-enrollment)

Study Sites (2)

Loading locations...

Similar Trials